| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ... Journal of clinical oncology 26 (8), 1275-1281, 2008 | 4008 | 2008 |
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 3359 | 2015 |
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy R Rouzier, CM Perou, WF Symmans, N Ibrahim, M Cristofanilli, ... Clinical cancer research 11 (16), 5678-5685, 2005 | 2714 | 2005 |
| Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ... Journal of Clinical Oncology 25 (28), 4414-4422, 2007 | 1966 | 2007 |
| Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JC Boughey, VJ Suman, EA Mittendorf, GM Ahrendt, LG Wilke, B Taback, ... Jama 310 (14), 1455-1461, 2013 | 1887 | 2013 |
| The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine JS Ross, EA Slodkowska, WF Symmans, L Pusztai, PM Ravdin, ... The oncologist 14 (4), 320-368, 2009 | 1566 | 2009 |
| Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ... Journal of Clinical Oncology 38 (12), 1346-1366, 2020 | 1534 | 2020 |
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ... Cancer research 68 (15), 6084-6091, 2008 | 1291 | 2008 |
| Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline LA Korde, MR Somerfield, LA Carey, JR Crews, N Denduluri, ES Hwang, ... Journal of Clinical Oncology 39 (13), 1485-1505, 2021 | 1064 | 2021 |
| The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy JS Ross, JA Fletcher, GP Linette, J Stec, E Clark, M Ayers, WF Symmans, ... The oncologist 8 (4), 307-325, 2003 | 1013 | 2003 |
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ... Clinical cancer research 19 (19), 5533-5540, 2013 | 949 | 2013 |
| The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models Nature biotechnology 28 (8), 827-838, 2010 | 939 | 2010 |
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ... Journal of clinical oncology 24 (26), 4236-4244, 2006 | 880 | 2006 |
| Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised … S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ... The lancet oncology 19 (4), 497-509, 2018 | 867 | 2018 |
| Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype WF Symmans, C Wei, R Gould, X Yu, Y Zhang, M Liu, A Walls, ... Journal of Clinical Oncology 35 (10), 1049-1060, 2017 | 785 | 2017 |
| Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively … R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ... JAMA oncology 6 (5), 676-684, 2020 | 778 | 2020 |
| Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1 JH Cha, WH Yang, W Xia, Y Wei, LC Chan, SO Lim, CW Li, T Kim, ... Molecular cell 71 (4), 606-620. e7, 2018 | 770 | 2018 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 749 | 2011 |
| An international Ki67 reproducibility study MYC Polley, SCY Leung, LM McShane, D Gao, JC Hugh, ... Journal of the National Cancer Institute 105 (24), 1897-1906, 2013 | 734 | 2013 |
| Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer M Ayers, WF Symmans, J Stec, AI Damokosh, E Clark, K Hess, M Lecocke, ... Journal of clinical oncology 22 (12), 2284-2293, 2004 | 693 | 2004 |
Christos HatzisAssociate Professor Adjunct of Medicine, Yale School of Medicine, Yale Cancer CenterVerified email at yale.edu
